NORTHVALE, N.J., June 7, 2012 /PRNewswire/ -- Orthofeet, a leading designer and manufacturer of biomechanically designed footwear, announced the showcasing of their portfolio of therapeutic and casual shoes at the American Diabetes Association (ADA) 72nd Scientific Sessions in Philadelphia, June 9-11.
"Our presence at this meeting the world's largest diabetes conference -- supports Orthofeet's corporate vision to improve mobility and quality of life for adults with this chronic disease," said Mark Koide, CEO, Orthofeet. For nearly three decades, Orthofeet has offered premium footwear designed to provide ultimate comfort and preventative care for those susceptible to diabetes-related foot complications.
"Patients with diabetes are highly vulnerable to a host of serious medical foot conditions including neuropathy, or loss of feeling, which can lead to blisters, ulcers and potential amputations of toes or lower limbs," said Dennis Janisse, Director of Scientific Affairs at Orthofeet. "We look forward to engaging with health care professionals on the importance of therapeutic shoes as part of a comprehensive foot health management plan."
Experts at the Orthofeet booth (#1849) will demonstrate how their therapeutic shoes are constructed to accommodate the needs of diabetes patients, including innovations in fasteners, non-binding construction, seamless lining and ergonomic soles. Orthofeet footwear is eligible for reimbursement by Medicare and most insurance companies.
Experts Discuss Foot Health
According to Janisse, this year's ADA Scientific Sessions will feature presentations on foot health from some of the most prestigious authorities, including:
- "The Diabetic Foot A Marriage of Team, Technology and Tenacity" Meet the Expert Session with David Armstrong, DPM, MD, PhD, Tuscon AZ
- "Inpatient Management of Diabetic Foot Disorders" moderated by Robert Frykberg, DPM, Phoenix, AZ
- "Depression and Not Specific Emotional Distress Predicts Diabetic Foot Ulcer Incidence" presented by Andrew Boulton, MD, PSc, FRCP and colleagues, Manchester, UK
"We're excited to be part of this important summit and hope to raise visibility as to proper footwear for those with diabetes," said Koide. "Our mission is to help patients avoid serious foot problems -- and to enhance mobility when those medical foot conditions already exist."
To learn more about Orthofeet's portfolio of therapeutic and casual footwear, visit www.orthofeet.com.
Orthofeet develops and manufactures a premium brand of specialty footwear biomechanically designed to provide consumers with ultimate mobility, comfort and protection for an improved quality of life. The company was established in 1985 by the Bar brothers, two biomedical engineers who pioneered innovations in footwear construction unmatched in the industry. In order to maintain its high level of quality and service, Orthofeet owns its production facilities. Orthofeet partners with medical professionals and DME providers throughout the US to provide patients with a great selection of therapeutic shoes, insoles and socks. For more information visit www.orthofeet.com
Note About Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, including those regarding Orthofeet's expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Orthofeet, or any other person, that such forward-looking statements will be achieved. The business and operations of Orthofeet are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.